Education
About Us
Working with TipRanks
Follow Us
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
2315 Stock Chart & Stats
HK$28.70
-HK$0.07(-0.93%)
At close: 4:00 PM EST
HK$28.70
-HK$0.07(-0.93%)
Day’s Range― - ―
52-Week RangeHK$7.71 - HK$63.00
Previous CloseN/A
Volume49.50K
Average Volume (3M)488.12K
Market Cap
HK$20.81B
Enterprise ValueHK$18.70B
Total Cash (Recent Filing)HK$486.84M
Total Debt (Recent Filing)HK$614.18M
Price to Earnings (P/E)141.4
Beta1.12
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding110,781,920
10 Day Avg. Volume755,126
30 Day Avg. Volume488,121
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)3.81
Price to Sales (P/S)3.24
P/FCF Ratio18.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$57.72Price Target Upside101.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margin And Operational EfficiencySustained gross margins near 80% reflect strong unit economics typical of proprietary biologics. High margin structure supports continued R&D investment and commercialization spending without immediate margin pressure, providing durable profitability buffer as products scale.
Strengthening Free Cash Flow GenerationRobust FCF growth and strong cash conversion indicate the business is improving internal funding capacity. Better cash generation reduces reliance on external financing, supports sustained pipeline investment, and improves long-term financial flexibility for partnerships or commercialization.
Platform-driven Partnership Revenue ModelA business model anchored in proprietary discovery platforms and collaborations diversifies revenue streams and shares development risk. Upfronts, milestones and royalties provide structural funding avenues and validate tech, enabling scale while limiting sole dependence on internal product launches.
Bears Say
Moderate LeverageDebt-to-equity near 0.7 is manageable but elevated for a growth biotech; it can constrain strategic flexibility and increase interest obligations. Over the medium term this may limit capacity for additional R&D spending or acquisitions without raising equity or refinancing under less favorable terms.
Historical Profitability VolatilityPast swings in profitability suggest earnings are sensitive to product timing, development milestones and cost variability. Persistent volatility complicates multi-quarter planning, investor predictability and may necessitate larger cash buffers or hedges that reduce capital available for growth initiatives.
Revenue Timing Risk From Partnership/Milestone DependenceHeavy reliance on milestone and royalty income creates lumpy, timing-dependent revenues that can produce uneven cash flows. This structural revenue concentration elevates execution and partner-risk, making steady growth and multi-period budgeting more challenging for corporate planning.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H News
2315 FAQ
What was Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price range in the past 12 months?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H lowest stock price was HK$7.71 and its highest was HK$63.00 in the past 12 months.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap is HK$20.81B.
When is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 37 days.
How were Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s earnings last quarter?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H released its earnings results on Aug 28, 2025. The company reported HK$0.132 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.132.
Is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H overvalued?
According to Wall Street analysts Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price is currently Undervalued.
Does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pay dividends?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H does not currently pay dividends.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H have?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding.
What happened to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price movement after its last earnings report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H reported an EPS of HK$0.132 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.697%.
Which hedge fund is a major shareholder of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2315
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
476.71%
12-Months-Change
Fundamentals
Return on Equity
16.13%
Trailing 12-Months
Asset Growth
4.29%
Trailing 12-Months
Company Description
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-regional clinical trials and two products are in Phase I clinical trials. It focuses on developing drugs in the areas of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company was founded in 2009 and is headquartered in Beijing, China. Beijing Biocytogen Co., Ltd. develops and prepares gene engineered animals to large-scale supply of animal models. It offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. The company's products include B-NDG mice, cre mouse models, cre rat models, B-p53 KO mice, B-ApoE KO mice, B-hIL6 mice, B-IL17-EGFP KI mice, B-TGFb1 cKO mice, genome- edited hESC, luciferase reported stable tumor cell lines, B-Pink1 KO rats, B-IL2rg KO rats, B-Cas9D10A cKI rats, B-ApoA4 KO rats, B-LDLR KO rats, B-Prkdc KO rats, B-Rag2 KO rats, B-tdTomato cKI rats, B-ApoE KO rats, B-hTnf mice, and B-hFcgrt (FcRn) mice. Beijing Biocytogen Co., Ltd. also develops antibody research and development platform and provides pharmacology services in the areas of tumor immunity, tumor and autoimmunity, and in vivo and in vitro pharmacology and pharmacology service platform. It also sells its products online. The company was founded in 2008 and is based in Beijing, China with additional locations in Beijing, Haimen, Jiangsu, Shanghai, China; Heidelberg, Germany; and Boston, the United States.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Earnings & Revenues
2315 Stock 12 Month Forecast
Average Price Target
HK$57.72
▲(101.11% Upside)
Technical Analysis
Ascletis Pharma, Inc.
―
Lepu Biopharma Co. Ltd. Class H
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---